Sunday, November 17, 2024 11:31:57 AM
suit,
That’s actually a pretty accurate statement generally speaking — it’s also common sense. Pharmaceutical collaborations/deals often involve an initial upfront payment, followed by milestone-based payments tied to specific development, regulatory, or sales goals. There’s nothing revolutionary about those terms of doing business—seems rather standard to me.
Regarding the “narrative” we’re supposedly trying to fit, we have yet to discover any specifics about the contractual agreements/collaborations cited in the recent 10-Q beyond those that were already announced. Of course, there are some reasonable possibilities that we can speculate about based on current or recently concluded clinical trials involving combos with DCVax-L (UCLA), and combos with the other dendritic cell technology that NWBO owns (Roswell).
https://www.sec.gov/ix?doc=/Archives/edgar/data/1072379/000141057824001879/nwbo-20240930x10q.htm
https://nwbio.com/audio-of-nwbio-2023-annual-shareholders-meeting/
https://www.nature.com/articles/s41467-024-48073-y
That’s actually a pretty accurate statement generally speaking — it’s also common sense. Pharmaceutical collaborations/deals often involve an initial upfront payment, followed by milestone-based payments tied to specific development, regulatory, or sales goals. There’s nothing revolutionary about those terms of doing business—seems rather standard to me.
Regarding the “narrative” we’re supposedly trying to fit, we have yet to discover any specifics about the contractual agreements/collaborations cited in the recent 10-Q beyond those that were already announced. Of course, there are some reasonable possibilities that we can speculate about based on current or recently concluded clinical trials involving combos with DCVax-L (UCLA), and combos with the other dendritic cell technology that NWBO owns (Roswell).
https://www.sec.gov/ix?doc=/Archives/edgar/data/1072379/000141057824001879/nwbo-20240930x10q.htm
https://nwbio.com/audio-of-nwbio-2023-annual-shareholders-meeting/
https://www.nature.com/articles/s41467-024-48073-y
Bullish
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
Recent NWBO News
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic • PR Newswire (US) • 04/21/2026 01:30:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 04/21/2026 04:15:08 AM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
